Virtus Investment Advisers’s Amicus Therapeutics FOLD Stock Holding History

Virtus Investment Advisers’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-64,777	Closed	-$922K	–	469
2025 Q4	$922K	Sell	64,777 -7,248	-10%	-$71.2K	0.25%	136
2025 Q3	$568K	Hold	72,025	–	–	0.16%	192
2025 Q2	$413K	Buy	72,025 +36,655	+104%	+$237K	0.14%	223
2025 Q1	$289K	Buy	35,370 +20,270	+134%	+$188K	0.08%	244
2024 Q4	$142K	Buy	+15,100	New	+$157K	0.11%	227

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Virtus Investment Advisers's FOLD Position: Q1 2026 in Review

Virtus Investment Advisers sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 64,777 shares — an estimated $922K sold.

Virtus Investment Advisers first reported a position in FOLD in Q4 2024 and held it in 5 quarters. The position peaked at $922K in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Virtus Investment Advisers reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
Virtus Investment Advisers sold 64,777 Amicus Therapeutics shares in Q1 2026, an estimated $922K.
Virtus Investment Advisers first reported a position in Amicus Therapeutics in Q4 2024 and held it in 5 quarters.
Virtus Investment Advisers's Amicus Therapeutics position peaked at $922K in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.